2020
30-OR: Empagliflozin Delays Need for Insulin Initiation in Patients with Type 2 Diabetes and Cardiovascular Disease: Findings from EMPA-REG OUTCOME
VADUGANATHAN M, SATTAR N, FITCHETT D, OFSTAD A, BRUECKMANN M, GEORGE J, VERMA S, MATTHEUS M, WANNER C, INZUCCHI S, ZINMAN B, BUTLER J. 30-OR: Empagliflozin Delays Need for Insulin Initiation in Patients with Type 2 Diabetes and Cardiovascular Disease: Findings from EMPA-REG OUTCOME. Diabetes 2020, 69 DOI: 10.2337/db20-30-or.Peer-Reviewed Original ResearchInsulin-naïve patientsInsulin useBackground glucose-lowering therapyEMPA-REG OUTCOMEInsulin dose increasesInsulin-treated patientsGlucose-lowering therapyEmpagliflozin 10T2D durationInsulin doseT2D diagnosisInsulin needsPlaceboPatientsWeight gainKey covariatesDose increaseInsulinTreatment effectsNew initiationHypoglycemiaT2DTherapyYrDiagnosis
2018
Noradrenergic Activity in the Human Brain: A Mechanism Supporting the Defense Against Hypoglycemia
Belfort-DeAguiar R, Gallezot JD, Hwang JJ, Elshafie A, Yeckel CW, Chan O, Carson RE, Ding YS, Sherwin RS. Noradrenergic Activity in the Human Brain: A Mechanism Supporting the Defense Against Hypoglycemia. The Journal Of Clinical Endocrinology & Metabolism 2018, 103: 2244-2252. PMID: 29590401, PMCID: PMC6456998, DOI: 10.1210/jc.2017-02717.Peer-Reviewed Original ResearchConceptsHyperinsulinemic-hypoglycemic clampRaphe nucleusCounterregulatory hormonal responsesInsulin-treated patientsOptimal glycemic controlPositron emission tomographic imagingGlucose infusion rateBrain responsesLean healthy volunteersEmission tomographic imagingGlycemic controlNA outputGlucagon levelsPlasma epinephrineNoradrenergic activationNA responseNoradrenergic activityAutonomic outputIntravenous injectionHealthy volunteersInfusion rateHypoglycemiaMotor activityGrowth hormoneHormonal responses
2015
C‐peptide levels in pediatric type 2 diabetes in the Pediatric Diabetes Consortium T2D Clinic Registry
Gregg B, Connor CG, Cheng P, Ruedy KJ, Beck RW, Kollman C, Schatz D, Cengiz E, Tamborlane WV, Klingensmith GJ, Lee JM, Consortium F. C‐peptide levels in pediatric type 2 diabetes in the Pediatric Diabetes Consortium T2D Clinic Registry. Pediatric Diabetes 2015, 17: 274-280. PMID: 25940861, DOI: 10.1111/pedi.12280.Peer-Reviewed Original ResearchConceptsC-peptide levelsC-peptide measurementsLower body mass indexPediatric type 2 diabetesInsulin-treated patientsEndogenous insulin secretionPediatric diabetes centersC-peptide valuesBody mass indexType 2 diabetesT2D durationInsulin therapyClinical factorsDiabetes CenterClinic registryMass indexC-peptideInsulin secretionInsulin treatmentLarge cohortT2DMetabolic controlType 2Biologic dataRegistry
1998
Paradoxic Decreases in Atherosclerotic Plaque Mass in Insulin-Treated Diabetic Patients
Kornowski R, Mintz G, Lansky A, Hong M, Kent K, Pichard A, Satler L, Popma J, Bucher T, Leon M. Paradoxic Decreases in Atherosclerotic Plaque Mass in Insulin-Treated Diabetic Patients. The American Journal Of Cardiology 1998, 81: 1298-1304. PMID: 9631966, DOI: 10.1016/s0002-9149(98)00157-x.Peer-Reviewed Original ResearchConceptsArterial areaPlaque accumulationLumen compromiseDe novo native coronary stenosisInsulin-treated patientsInsulin-treated diabeticsNative coronary stenosisMultivariate linear regression analysisAtherosclerotic lesion formationBody surface areaParadoxic decreaseInsulin useDiabetes mellitusDiabetic patientsIndependent predictorsRemodeling indexAnginal syndromePlaque burdenCoronary stenosisArterial shrinkageInsulin treatmentPlaque massIntravascular ultrasoundLinear regression analysisReference segments
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply